Janus Henderson Global Life Sciences N (JFNNX)

Fund Assets	6.03B
Expense Ratio	0.68%
Min. Investment	$1,000,000
Turnover	30.00%
Dividend (ttm)	0.43
Dividend Yield	0.50%
Dividend Growth	22.81%
Payout Frequency	Annual
Ex-Dividend Date	Dec 5, 2025

Previous Close	86.06
YTD Return	7.18%
1-Year Return	22.86%
5-Year Return	59.01%
52-Week Low	73.75
52-Week High	94.11
Beta (5Y)	0.79
Holdings	98
Inception Date	Jan 26, 2018

About JFNNX

Janus Henderson Global Life Sciences Fund is an actively managed sector equity health fund launched by Janus Henderson in 2018. Its primary function is to provide long-term capital growth by investing in companies across the life sciences sector, including biotechnology, health care services, medical devices, and pharmaceuticals. The fund aims to outperform the MSCI World Health Care Index by at least 2% per annum over five years. It invests at least 80% of its assets in equities of companies addressing unmet medical needs or improving health care efficiencies. The fund is notable for its balanced portfolio approach and is managed by an experienced team specializing in health care science and business. This asset plays a significant role in the health care investment landscape, offering a diversified portfolio that aligns with the broader health care industry.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: High
• Risk Rating: Average
• Stock Exchange: Nasdaq
• Ticker Symbol: JFNNX
• Share Class: Class N
• Index: MSCI World/Health Care NR

Performance

JFNNX had a total return of 22.86% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.24%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNIX	Class I	0.78%
JNGLX	Class D	0.81%
JAGLX	Class T	0.92%
JFNAX	Class A	1.00%

Top 10 Holdings

42.22% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	9.05%
Johnson & Johnson	JNJ	7.48%
AbbVie Inc.	ABBV	4.63%
UnitedHealth Group Incorporated	UNH	4.33%
AstraZeneca PLC	AZN	3.50%
Thermo Fisher Scientific Inc.	TMO	2.92%
Novartis AG ADR	NVSN.MX	2.78%
Roche Holding AG	ROP	2.63%
argenx SE	ARGX	2.55%
Abbott Laboratories	ABT	2.36%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 5, 2025	$3.76513	Dec 5, 2025
Dec 6, 2024	$4.06789	Dec 6, 2024
Dec 7, 2023	$3.00343	Dec 7, 2023
Dec 20, 2022	$0.27276	Dec 20, 2022
Dec 20, 2021	$6.91402	Dec 20, 2021
Dec 17, 2020	$5.65748	Dec 17, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 8, 2026

Data Sources Report a data error